Enanta Pharmaceuticals to Participate in September Investor Conferences

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

ZNTLZentalis2026-09-02 20:05 EST

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

AVTXAvalo Therapeutics2026-09-03 11:00 EST

Avalo Therapeutics to Participate in Upcoming Investor Conferences

INVAInnoviva2026-09-02 12:00 EST

Innoviva to Participate in Upcoming Investor Conferences

SABSSAB Biotherapeutics2026-09-01 12:30 EST

SAB BIO to Participate in Upcoming Investor Conferences

SCYXSCYNEXIS2026-09-01 12:30 EST

SCYNEXIS to Participate in Upcoming Investor Conferences

CABACabaletta Bio2026-09-01 12:00 EST

Cabaletta Bio to Participate in Upcoming Investor Conferences

View all latest news

Enanta Pharmaceuticals

Small-Molecule Research Platform Enanta Pharmaceuticals discovers and develops oral small molecules for virology and immunology. Its portfolio applies structure-based drug design to targets that may support convenient, once-daily treatment. EDP-978 KIT Inhibitor EDP-978 is an oral KIT inhibitor in Phase 1 development for chronic...